Immune System News and Research

RSS

Baxter submits GAMMAGARD LIQUID sBLA to FDA for treatment of MMN

Baxter International Inc. today announced that the company has submitted a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for approval of GAMMAGARD LIQUID 10% for the treatment of multifocal motor neuropathy.

From Baxter International Inc. 9 Jan 2012

Novel target in artery plaque identified as potential therapeutic intervention

A new study by NYU Langone Medical Center researchers identified a new culprit that leads to atherosclerosis, the accumulation of fat and cholesterol that hardens into plaque and narrows arteries.

9 Jan 2012

Merck selects Idera Pharmaceuticals' TLR agonists for evaluation, use as vaccine adjuvant candidates

Idera Pharmaceuticals, Inc. today announced that Merck, known as MSD outside the United States and Canada, has selected several novel Toll-like Receptor agonists targeted to TLR7, TLR8 or TLR9 for evaluation and use as vaccine adjuvant candidates under the companies' collaboration and license agreement.

9 Jan 2012

TRON uses Ingenuity Variant Analysis to identify cancer driver variants

Ingenuity Systems, a leading provider of information and analysis solutions for life science researchers, today announced that TRON has used Ingenuity Variant Analysis to identify cancer driver variants that inform the development of an experimental individualized RNA-based therapeutic.

9 Jan 2012

Enrollment complete in Diamyd Phase II study for type 1 diabetes

A total of 50 children aged four and older with a high risk of developing type 1 diabetes have been enrolled in a researcher-initiated Phase II study, DiAPREV-IT, with Diamyd Medical's diabetes vaccine Diamyd. The study is thus fully recruited.

9 Jan 2012

Colby's JVRS-100 enhances immunogenicity, cross-protective efficacy of H5N1 influenza vaccine

Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus protection.

9 Jan 2012

MPIIB, QIAGEN partner to develop latent TB diagnostic test

QIAGEN N.V. and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime.

From QIAGEN Manchester Limited 9 Jan 2012

Positive results from BioCryst's BCX4208 Phase 2b study on gout

BioCryst Pharmaceuticals, Inc. announced long-term results from the extension phase of its randomized Phase 2b study of BCX4208 added to allopurinol in patients with gout who had failed to reach the serum uric acid (sUA) therapeutic goal of <6 mg/dL on allopurinol alone.

8 Jan 2012

Proteomics: Thermo Fisher Scientific and PREMIER Biosoft to co-market SimGlycan software

Thermo Fisher Scientific Inc., the world leader in serving science, and PREMIER Biosoft, have announced an agreement to co-market PREMIER Biosoft’s SimGlycan® software. The agreement aims to advance glycobiology by dramatically speeding the characterization of complex glycans through automated interpretation of the rich data produced by Thermo Scientific mass spectrometer systems.

From Thermo Fisher Scientific Inc. 8 Jan 2012

Contaminated cantaloupes carrying listeria

According to federal health officials last week, at least 13 people are dead amid 72 sickened in 18 states in an outbreak of listeria food poisoning tied to contaminated cantaloupes.

8 Jan 2012

New Zealand life science and health IT companies to showcase their products in San Francisco

New Zealand is well known for its wines and stunning scenery, but the country is also a great source of innovation in the life sciences. A delegation of New Zealand life sciences companies who have reached key stages in their development are joining the throngs of international therapeutics, medical device and health IT companies in San Francisco, January 9 - 12 to showcase their products and capabilities to potential corporate partners and investors.

7 Jan 2012

AnaptysBio enters new strategic alliances for antibody discovery

AnaptysBio, Inc., a privately-held therapeutic antibody company, today announced the initiation of new strategic alliances with two partners: Novartis and an undisclosed second pharmaceutical company.

7 Jan 2012

Study provides hope for stimulating remyelination in MS patients

Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.

7 Jan 2012

Stimflora launches new dietary health product

An exciting new dietary health product has been launched which promotes healthy digestion while strengthening the immune system.

7 Jan 2012

PCI Biotech focuses on localised cancer therapy with minimum side effects

Side effects are currently the biggest problem with any cancer treatment. A Norwegian biotech company is drawing closer to the goal of creating a treatment which kills only cancer cells, leaving other cells unaffected.

7 Jan 2012

Study on benefits of Brain Wave Vibration meditation method

BEST Life Media, publisher of the Award Winning Brain Wave Vibration, and other books on health and wellness and the mind-body connection, is pleased to announce the results of a recent study concerning the Brain Wave Vibration meditation method.

7 Jan 2012

Study shows how Epstein-Barr virus triggers MS

A new study from researchers at Queen Mary, University of London shows how a particular virus tricks the immune system into triggering inflammation and nerve cell damage in the brain, which is known to cause MS.

6 Jan 2012

SonoPhoto Dynamic Therapy shows promise against squamous cell carcinoma

George Miller developed an ulcer on his bottom lip that began to bleed. His doctor sent cell scrapings to a pathologist, and diagnosed Miller with squamous cell carcinoma (SCC). According to TMD Limited, a medical tourism company, squamous cell carcinoma is the 2nd most common cancer in humans and other animals.

6 Jan 2012

Wake Forest Baptist participates in novel brain tumor vaccine clinical trial

A national clinical trial testing the efficacy of a novel brain tumor vaccine has begun at Wake Forest Baptist Medical Center, the only facility in the Southeast to participate.

6 Jan 2012

New laboratory approach could aid brain recovery

In humans, active periods of the debilitating disease Multiple Sclerosis (MS) can last for mere minutes or extend to weeks at a time. They're caused by lesions in the brain that develop, partly heal, and then recur. Research into a cure has been difficult, because to date scientists have not been able to replicate these brain recurring symptoms in laboratory mice. That's frustrating because these lab animals, known as animal "models," are the primary tool for research into the mechanisms and potential treatments for MS.

6 Jan 2012